✦ LIBER ✦

Etoposide combination therapy for small cell carcinoma of the lung

✍ Scribed by R. P. Abratt; P. A. Willcox; R. H. Hewitson

Publisher: Springer
Year: 1987
Tongue: English
Weight: 191 KB
Volume: 20
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00252967

No coin nor oath required. For personal study only.

✦ Synopsis

Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to patients with limited disease after chemotherapy. In limited-disease and extensive-disease patients the median survival was 12 and 6 months respectively. The 2-year survival rate (life table) in limited-disease patients was 26%. Treatment morbidity was low. A prospective randomised trial is being undertaken to further evaluate the role of oral etoposide in combination chemotherapy.

📜 SIMILAR VOLUMES

Combination chemotherapy for small cell

Combination chemotherapy for small cell carcinoma of the lung

✍ E. D. Gilby; Professor P. K. Bondy; R. L. Morgan; T. J. McElwain 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 575 KB

Combination chemotherapy and radiation t

Combination chemotherapy and radiation therapy in small cell carcinoma of the lung

✍ Robert T. Eagan; L. Herbert Maurer; R. Jackson Forcier; Marchant Tulloh 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 786 KB

Twenty-eight patients with small cell carcinoma of the lung were studied for their response to combination chemotherapy and radiation therapy, frequency of bone marrow metastases, and clinically evident hormonal syndromes. Seventeen of 19 evaluable patients who received cyclic monthly courses of hig

Combined modality therapy for locally ad

Combined modality therapy for locally advanced non-small cell lung carcinoma

✍ D. Recine; K. Rowland; S. Reddy; M. S. Lee; P. Bonomi; S. Taylor IV; L. P. Faber 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 691 KB

Multi-modality treatment consisting of cisplatin, VP-16, and 5-fluorouracil chemotherapy given concomitantly with external beam radiation was used to treat 64 patients with locally advanced Stage I11 non-small cell lung carcinoma. This regimen was used in a preoperative fashion for four cycles in pa

Recent advances in etoposide therapy for

Recent advances in etoposide therapy for non-small cell lung cancer

✍ Philip Bonomi 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

Non-small cell lung cancer (NSCLC) continues to be a major health problem in the US. In 1990, approximately 120,000 new cases will be diagnosed, and the majority of these patients will have either unresectable disease or resected disease that has a relatively low chance of being cured. A variety of

Cisplatin, doxorubicin, cyclophosphamide

Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer

✍ Joseph Aisner; Margaret Y. Whitacre; Daniel R. Budman; Kathy Propert; Gary Strau 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 442 KB

Combination radiotherapy and chemotherap

Combination radiotherapy and chemotherapy for small cell carcinoma of the lung

✍ Goldberg, R. S. ;Joss, R. A. ;Bedwinek, J. ;Yates, J. W. ;Krakoff, I. H. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB

Twenty previously untreated patients with small cell carcinoma of the lung were treated with cyclophosphamide, 400 mg/m2 and Adriamycin, 40 mg/m2 IV on day 1, followed by cytosine arabinoside, 20 mg/m2, every 12 hours subcutaneously on days 5--9; this regimen was repeated every 28 days. On days 14--